- Home
- POLE vs AVIR Comparison
POLE vs AVIR Comparison
Compare POLE & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLE
- AVIR
- Stock Information
- Founded
- POLE 2024
- AVIR 2012
- Country
- POLE United States
- AVIR United States
- Employees
- POLE N/A
- AVIR N/A
- Industry
- POLE
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- POLE
- AVIR Health Care
- Exchange
- POLE NYSE
- AVIR Nasdaq
- Market Cap
- POLE 299.8M
- AVIR 252.5M
- IPO Year
- POLE 2024
- AVIR 2020
- Fundamental
- Price
- POLE $10.33
- AVIR $3.19
- Analyst Decision
- POLE
- AVIR Hold
- Analyst Count
- POLE 0
- AVIR 1
- Target Price
- POLE N/A
- AVIR $6.00
- AVG Volume (30 Days)
- POLE 46.9K
- AVIR 424.5K
- Earning Date
- POLE 01-01-0001
- AVIR 05-12-2025
- Dividend Yield
- POLE N/A
- AVIR N/A
- EPS Growth
- POLE N/A
- AVIR N/A
- EPS
- POLE N/A
- AVIR N/A
- Revenue
- POLE N/A
- AVIR N/A
- Revenue This Year
- POLE N/A
- AVIR N/A
- Revenue Next Year
- POLE N/A
- AVIR N/A
- P/E Ratio
- POLE $58.36
- AVIR N/A
- Revenue Growth
- POLE N/A
- AVIR N/A
- 52 Week Low
- POLE $9.94
- AVIR $2.46
- 52 Week High
- POLE $11.16
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- POLE N/A
- AVIR 63.63
- Support Level
- POLE N/A
- AVIR $2.92
- Resistance Level
- POLE N/A
- AVIR $3.29
- Average True Range (ATR)
- POLE 0.00
- AVIR 0.14
- MACD
- POLE 0.00
- AVIR 0.05
- Stochastic Oscillator
- POLE 0.00
- AVIR 86.33
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).